XM-ONE® crossmatching provides information on presence of non-HLA antibodies compared to the currently used lymphocyte crossmatch tests.
The study showed that the XM-ONE® test can detect an antibody population not possible to detect with lymphocyte crossmatch tests that is strongly associated with rejection episodes and reduced kidney function after transplantation. The authors suggests that the XM-ONE® crossmatch test can identify patients at risk of antibody-mediated rejections.